ReviewKidney medicine2026
Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives.
Review in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria.Journal of clinical medicine · 2026Article
- Review
- Neutrophils in Kidney Disease: Linking Neutrophil Function and Microenvironment to Therapeutic Targets.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based therapies initially developed for the management of type 2 diabetes. In addition to improving glycemic control and promoting weight loss, these agents have demonstrated cardiovascular and potential renal benefits. This review explores the mechanisms by which GLP-1 receptor agonists may exert renoprotective effects, including modulation of inflammation, oxidative stress, fibrosis, endothelial dysfunction, and glomerular hemodynamics. We examine the expression of GLP-1 receptors in renal tissues and discuss preclinical data supporting their role in preserving kidney function, even in nondiabetic populations. Clinical trials such as SUSTAIN-6, REWIND, and FLOW provide evidence of GLP-1 receptor agonists reducing albuminuria and attenuating estimated glomerular filtration rate decline in patients with diabetic chronic kidney disease. Although further research is needed to define their role in nondiabetic chronic kidney disease, the growing body of evidence highlights GLP-1 receptor agonists as important agents in kidney protection. By integrating cellular mechanisms with clinical outcomes, this review offers a comprehensive understanding of their emerging role in the management of chronic kidney disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.